ACTRN12619001655134招募中2 期
AMLM25: An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with VENetoclax in Elderly (INTERVENE) Acute Myeloid Leukaemia
The Australasian Leukaemia and Lymphoma Group0 个研究点目标入组 208 人开始时间: 2019年11月27日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 208
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 60 Years 至 o limit（—）
- 性别
- All
入选标准
- •Age, greater than or equal to 60 years.
- •- AML (excluding acute promyelocytic leukaemia and core binding factor AML) stratified by MRC 2010 criteria
- •a.Non-adverse cytogenetic risk or
- •b.Adverse cytogenetic risk (inclusive of failed cytogenetic analysis)
- •- ECOG performance status 0-2
- •- No prior treatment for AML (except hydroxyurea or thioguanine)
- •- Adequate liver function (AST or ALT less than 1.5x ULN and bilirubin les than or equal to 1.5x ULN*). *unless considered related to AML or Gilbert’s syndrome
- •- Adequate renal function as demonstrated by a Cockcroft Gault formula creatinine clearance of greater than 30mL/min.
排除标准
- •- Any serious medical, psychological or social problem which the investigator feels may interfere with the procedures or evaluations of the study including:
- •a.Malabsorption syndrome or other condition that precludes enteral route of administration
- •b.Significant cardiovascular disability status of New York Heart Association Class greater than 2.
- •c.Significant chronic respiratory disease that requires continuous oxygen
- •- WBC greater than 25x109/L. Hydroxyurea may be used to control the white blood cell count
- •- Acute promyelocytic leukaemia
- •- Core binding factor AML including t(8;21)(q22;q22) or inv(16)(p13. 1q22)/t(16;16)(p13.1;q22)
- •- Antecedent chronic myeloid leukaemia (CML) or CML in blast phase
- •- Antecedent myelofibrosis (including primary and secondary)
- •- Active CNS leukaemia
- •- Prior exposure to venetoclax, FLT3 inhibitors or pracinostat
- •- Exposure to other investigational agents within 30 days or 5 half lives
- •- Known hypersensitivity to any of the investigational agents
- •- History of other malignancy requiring active systemic treatment or which is likely to result in an expected survival time of less than 2 years
- •- Subject is known to be positive for HIV
- •- Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:
- •a.Clinically significant active systemic infection (viral, bacterial or fungal) requiring therapy
- •b.Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface (HBs) antigen negative-, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate
- •- Active bleeding or clinically relevant prolongation of APTT or INR
- •- QT-interval corrected according to Fridericia’s formula (QTcF) greater than 450ms
- •- Treatment with any of the following within 7 days prior to the first dose of study drug
- •a.Steroid therapy for anti-neoplastic intent
- •b.Moderate or strong cytochrome P450 3A (CYP3A inhibitors)
- •c.Moderate or strong CYP3A inducers
- •- Administration or consumption of any of the following within 3 days prior to the first dose of study drug:
- •a.Grapefruit or grapefruit products
- •b.Seville oranges (including marmalade containing Seville oranges)
- •c.Star fruit
- •- (For Pracinostat containing arm only) Current smokers (use of patches, chewing gums or vaping nicotine containing fluids is permitted). Patients who stopped smoking at least 8 days prior to first pracinostat dosing can be enrolled, provided they refrain from smoking during the whole study.
- •- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for at least 4 months after stopping medication. Highly effective contraception methods include:
- •a.Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
- •b.Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by foll
研究者
相似试验
尚未招募
1 期
AMLM26/T2 INTERCEPT: A multi-arm trial for patients with acute myeloid leukaemia investigating new treatments which target early relapse and changes in disease characteristics - Ivosidenib + Venetoclaxacute myeloid leukaemiaCancer - Leukaemia - Acute leukaemiaACTRN12624000141549Australasian Leukaemia & Lymphoma Group69
招募中
不适用
AMLM26 INTERCEPT: A multi-arm trial for patients with acute myeloid leukaemia investigating new treatments which target early relapse and changes in disease characteristics - The Master ProtocolAcute myeloid leukaemia (AML)Cancer - Leukaemia - Acute leukaemiaACTRN12621000439842Australasian Leukaemia & Lymphoma Group500
进行中（未招募）
不适用
A study of Aleglitazar in Patients with Stable Cardiovascular disease and Glucose Abnormalities- Stable Cardiovascular Disease and- Diabetes Mellitus Type 2 or Pre-diabetesMedDRA version: 16.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 16.0Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849MedDRA version: 16.0Level: LLTClassification code 10036481Term: Pre-diabetesSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-000671-16-CZF. Hoffmann-La Roche Ltd19,000
进行中（未招募）
不适用
A study of Aleglitazar in Patients with Stable Cardiovascular disease and Glucose AbnormalitiesEUCTR2012-000671-16-PLF. Hoffmann-La Roche Ltd19,000
进行中（未招募）
不适用
A study of Aleglitazar in Patients with Stable Cardiovascular disease and Glucose AbnormalitiesEUCTR2012-000671-16-ATF. Hoffmann-La Roche Ltd19,000